Pacritinib (INN codenamed SB1518) is a Janus kinase inhibitor that is being developed for the treatment of myelofibrosis. It mainly inhibits Janus kinase 2 (JAK2). The drug is in Phase III clinical trials as of 2013. The drug was discovered in Singapore at the labs of S*BIO Pte using structure-based design.
This page contains content from the copyrighted Wikipedia article "Pacritinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
